Drug Profile


Alternative Names: AZD-0548; LAS 100977; OD LABA

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Laboratorios Almirall
  • Developer Almirall S.A.
  • Class Antiasthmatics; Bronchodilators
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 09 Sep 2017 AstraZeneca plans a phase I trial for Asthma in Germany (NCT03273127)
  • 07 Sep 2017 AstraZeneca plans a phase II trial for Asthma in Bulgaria, Germany, Hungary, Japan, Poland, South Africa, Ukraine and USA (EudraCT2016-004140-10)
  • 06 Apr 2017 AstraZeneca completes a phase I trial for Chronic obstructive pulmonary disease and asthma (In voulnteers) in Germany (NCT02967159)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top